Evidence map›Paper›PMID 34473380›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2021

Zoledronate alters natural progression of tissue-engineered vascular grafts.

Yu-Chun Chang, Junlang Li, Gabriel Mirhaidari, Jacob Zbinden, Jenny Barker, Kevin Blum, James Reinhardt, Cameron Best, John Kelly, Toshihiro Shoji and 2 more

Open access · greenAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Yu-Chun ChangCenter for Regenerative Medicine at the Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio, USA.
Junlang LiCenter for Regenerative Medicine at the Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio, USA.
Gabriel MirhaidariCenter for Regenerative Medicine at the Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio, USA.
Jacob ZbindenCenter for Regenerative Medicine at the Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio, USA.
Jenny BarkerCenter for Regenerative Medicine at the Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio, USA.
Kevin BlumCenter for Regenerative Medicine at the Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio, USA.
James ReinhardtCenter for Regenerative Medicine at the Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio, USA.ORCID 0000-0001-8406-8421
Cameron BestCenter for Regenerative Medicine at the Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio, USA.ORCID 0000-0001-7426-0137
John KellyCenter for Regenerative Medicine at the Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio, USA.
Toshihiro ShojiCenter for Regenerative Medicine at the Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio, USA.
Tai YiCenter for Regenerative Medicine at the Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio, USA.
Christopher BreuerCenter for Regenerative Medicine at the Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio, USA.
Nationwide Children's Hospital · US

Funding

Mechanisms of Vascular Neotissue Formation In Tissue Engineered Vascular GraftsR01HL098228 · NHLBI · YALE UNIVERSITY · PI BREUER, CHRISTOPHER KANE · 2010 to 2018
$3.6M
Advanced Research Training in Immunology for Surgery Trainees (ARTIST)T32AI106704 · NIAID · OHIO STATE UNIVERSITY · PI GINNY L BUMGARDNER, Jon R Wisler · 2014 to 2026
$3.5M
Training in Congenital and Acquired Heart DiseaseT32HL098039 · NHLBI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI GARG, VIDU, MOHLER, PETER J. · 2009 to 2019
$2.5M
Targeting LYST-Mediated Tissue-Engineered Vascular Graft StenosisF31HL145962 · NHLBI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI BEST, CAMERON AUSTIN · 2019 to 2019
$12k
American Heart Association-American Stroke Association 18POST33990231NHLBI NIH HHS F31 HL145962NHLBI NIH HHS R01 HL098228NHLBI NIH HHS T32 HL098039NIAID NIH HHS T32 AI106704
6 · The paper itself

Abstract

Macrophages are a critical driver of neovessel formation in tissue-engineered vascular grafts (TEVGs), but also contribute to graft stenosis, a leading clinical trial complication. Macrophage depletion via liposomal delivery of clodronate, a first-generation bisphosphonate, mitigates stenosis, but simultaneously leads to a complete lack of tissue development in TEVGs. This result and the associated difficulty of utilizing liposomal delivery means that clodronate may not be an ideal means of preventing graft stenosis. Newer generation bisphosphonates, such as zoledronate, may have differential effects on graft development with more facile drug delivery. We sought to examine the effect of zoledronate on TEVG neotissue formation and its potential application for mitigating TEVG stenosis. Thus, mice implanted with TEVGs received zoledronate or no treatment and were monitored by serial ultrasound for graft dilation and stenosis. After two weeks, TEVGs were explanted for histological examination. The overall graft area and remaining graft material (polyglycolic-acid) were higher in the zoledronate treatment group. These effects were associated with a corresponding decrease in macrophage infiltration. In addition, zoledronate affected the deposition of collagen in TEVGs, specifically, total and mature collagen. These differences may be, in part, explained by a depletion of leukocytes within the bone marrow that subsequently led to a decrease in the number of tissue-infiltrating macrophages. TEVGs from zoledronate-treated mice demonstrated a significantly greater degree of smooth muscle cell presence. There was no statistical difference in graft patency between treatment and control groups. While zoledronate led to a decrease in the number of macrophages in the TEVGs, the severity of stenosis appears to have increased significantly. Zoledronate treatment demonstrates that the process of smooth muscle cell-mediated neointimal hyperplasia may occur separately from a macrophage-mediated mechanism.

Indexed as

AnimalsBlood Vessel ProsthesisBone Density Conservation AgentsFemaleMiceMice, Inbred C57BLNeointimaTissue EngineeringTissue ScaffoldsVascular GraftingZoledronic AcidBone Density Conservation AgentsZoledronic Acidbisphosphonatesinflammationmacrophagesneovesselstenosis

Identifiers

PMID34473380
PMCPMC8647171
OpenAlexW3198857211

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.